Lower-dose apixaban remains safe, effective in atrial fibrillation patients
Although drug concentrations of apixaban were lower in patients receiving 2.5 mg twice daily compared with 5 mg twice daily, the effects of dose adjustment to 2.5 mg relative to warfarin were consistent for coagulation biomarkers and clinical outcomes, results of the ARISTOTLE* trial have shown.
Lower-dose apixaban remains safe, effective in atrial fibrillation patients
19 Mar 2020